Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1,407 INR | +3.64% | +1.59% | +12.87% |
May. 15 | Indian Equities Posts Mild Losses on Wednesday Ahead of US Consumer Inflation Data | MT |
May. 15 | INDIA STOCKS-Cipla lifts Indian shares at the open; Canara Bank rises on MSCI inclusion | RE |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
- According to Refinitiv, the company's ESG score for its industry is good.
Strengths
- Before interest, taxes, depreciation and amortization, the company's margins are particularly high.
- The company returns high margins, thereby supporting business profitability.
- Thanks to a sound financial situation, the firm has significant leeway for investment.
- For the past year, analysts covering the stock have been revising their EPS expectations upwards in a significant manner.
Weaknesses
- With a 2024 P/E ratio at 26.56 times the estimated earnings, the company operates at rather significant levels of earnings multiples.
- The company's enterprise value to sales, at 4.03 times its current sales, is high.
- In relation to the value of its tangible assets, the company's valuation appears relatively high.
- The valuation of the company is particularly high given the cash flows generated by its activity.
- The firm pays small or no dividend to shareholders. For that reason, it is not a yield company.
- Over the past twelve months, analysts' opinions have been revised negatively.
- The group usually releases earnings worse than estimated.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Pharmaceuticals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+12.87% | 13.12B | B+ | ||
+21.28% | 44.4B | B- | ||
+24.60% | 23.03B | B+ | ||
+19.22% | 15.14B | - | ||
+44.67% | 11.85B | B | ||
-8.33% | 6.99B | B+ | ||
-0.05% | 6.79B | - | - | |
-8.87% | 5.73B | - | - | |
+13.07% | 5.52B | B+ | ||
-8.02% | 4.62B | D+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- CIPLA Stock
- Ratings Cipla Limited